Compared to other benzodiazepines, it has reduced side effects such as impaired cognition, reaction times and coordination. which makes it best suited as an anxiolytic because of these reduced sides effects. With higher doses such as 40 mg of camazepam, impairments similar to those caused by other benzodiazepines manifest as disrupted sleep patterns and impaired cognitive performance. Animal studies have shown camazepam and its active metabolites possess anticonvulsant properties.Skin disorders have been reported with use of camazepam however. Camazepam is believed to increase attention. Unlike other benzodiazepines it does not disrupt normal sleep patterns. Camazepam has been shown in animal experiments to have a very low affinity for benzodiazepine receptors compared to other benzodiazepines. It is almost completely absorbed into the bloodstream after oral administration with, 90 percent bioavailability achieved in humans. Camazepam is metabolised into the active metabolite temazepam. Compared to temazepam, camazepam has shown roughly equal anxiolytic properties, and less anticonvulsant, sedative and motor-impairing properties.
^Tammaro, A; Picceo, MT; Gemmellaro, P; Bonaccorso, O (1977). "Camazepam versus placebo. A double-blind clinical study on geriatric patients suffering from psychic complaints. Short Communication". Arzneimittel-Forschung27 (11): 2177–8. PMID23793.
^Tallone, G; Ghirardi, P; Bianchi, MC; Ravaccia, F; Bruni, G; Loreti, P (1980). "Reaction time to acoustic or visual stimuli after administration of camazepam and diazepam in man". Arzneimittel-Forschung30 (6): 1021–4. PMID6106497.
^Ferrillo, F; Balestra, V; Carta, F; Nuvoli, G; Pintus, C; Rosadini, G (1984). "Comparison between the central effects of camazepam and temazepam. Computerized analysis of sleep recordings". Neuropsychobiology11 (1): 72–6. doi:10.1159/000118055. PMID6146112.
^Riva, R; Albani, F; Baruzzi, A (1982). "Quantitative determination of camazepam and its metabolite temazepam in man by gas-liquid chromatography with electron-capture detection". Il Farmaco; edizione pratica37 (1): 15–9. PMID6120096.